DRREDDY share price target 2026

Price target: support and resistanceComputed 30 Jun 2026

Support and resistance for DRREDDY are read inside the latest show; no spot was printed in the most recent editorial note.

Levels are read inside the latest show. The most recent editorial reference is Systematic Read on 9 Jun 2026.

These are structural reference lines, not a SEBI-registered price target. BazaarBaazi is independent media; the levels frame how the desk reads the DRREDDY chart, refreshed every end-of-day run.

The Crack Score, and how it is built57 / 100 · Constructive

The Crack Score is a deterministic 0 to 100 conviction number. Here is exactly what moved it for DRREDDY, so the figure is a transparent signal rather than a vibe.

Base 50, adjusted by the factors above and clamped to 0 to 100. How the Crack Score works.

About Dr. Reddy's Laboratories LimitedBusiness profile

What DRREDDY actually does, and the edge that holds its position.

Dr Reddys is the most geographically spread of the big Indian generics names, and that diversification is both its defence against any single market and the source of its odd Russia exposure. It operates across North America, Europe, Russia and the CIS, and India, making and selling branded generics, active pharmaceutical ingredients, biosimilars and proprietary drugs. The Russia and CIS business is a historically important revenue stream alongside US generics, and a growing biosimilars portfolio spans emerging and regulated markets, so the spread that cushions it also ties it to a geopolitically volatile geography peers largely avoid.

Dr Reddys has an integrated API-to-formulation capability that gives it cost control and supply assurance across molecules, which is a structural advantage during global supply-chain disruptions. Its presence across multiple geographies and therapy categories means it is less exposed to any single market cycle than single-geography generic peers.

The F&O viewHorizon · swing

How the futures and options structure on DRREDDY reads right now.

The futures and options read on DRREDDY leans to a two-way / range write. Strike-level positioning is read inside the latest show, against the printed spot. Single-stock F&O on DRREDDY is thinner than the index, so open-interest shifts read with more noise; the desk weights price structure over raw OI. This is a structural reading of positioning, not a derivatives trade recommendation.

Why it movedLatest editorial line

The most recent BazaarBaazi read on what is driving DRREDDY.

Systematic read: a disclosed, data-only model on real 1-year price structure.

Read in Systematic Read on 9 Jun 2026. Why DRREDDY moved, the living explainer, tracks every move on one URL.

The 2026 to 2030 pictureStructural read

What genuinely drives DRREDDY over a multi-year horizon. A structural read, not a price forecast.

Between 2026 and 2030, the drivers for Dr Reddys are US market new product launches reducing dependency on a small set of molecules, biosimilars scaling in the US and Europe, and the Russia-CIS business navigating a complex geopolitical environment. The key risks are USFDA action at any manufacturing facility and geopolitical disruption to the Russia business that has historically been a meaningful earnings contributor. What BazaarBaazi thinks: the multi-geography spread and API-to-formulation integration are genuine structural strengths, but the wildcard no score can model is Russia, a meaningful earnings contributor sitting in a geography where a sanction or currency move can swing the line in ways no fundamental read anticipates.

What to watch:

• US new product launches per year and the pipeline of pending ANDAs
• USFDA inspection outcomes for API and formulation facilities
• Russia and CIS business revenue trend given geopolitical volatility
• Biosimilar approvals and commercial launch timelines in US and European markets
• API segment revenue as an indicator of vertical integration leverage

Peers and how to compare5 listed names

The listed names DRREDDY is most often read against. Compare them on the same Crack Score and levels.

Live valuation readQ4 FY26 earnings · live spot

P/E, P/B, yield and the quality set for Dr. Reddy's Laboratories Limited, computed from the latest filed results times the live spot. The price-driven ratios (marked) refresh every session; ROE and margins hold until the next results.

Stored from Dr. Reddy's Laboratories Limited's filed results, as of 2026-06-30 and currency-checked. Price input Rs 1,357.10 from baked EOD spot. Open the calculator, move the price and watch every ratio react.

Latest filed resultsQ4 FY26

Dr. Reddy's Laboratories Limited's most recent quarter, parsed straight from the official NSE filing. Every figure links back to its primary source.

See every Q4 result the desk has read.

Earnings historyLast 8 quarters

Dr. Reddy's Laboratories Limited's official quarterly revenue, EPS and Result Pulse trail from the verified filings export. These are quarterly facts, not TTM valuation inputs.

What changed50 disclosures

Every recent official filing from Dr. Reddy's Laboratories Limited, straight from the exchange feed, with the BazaarBaazi Event Heat on the disclosure flow.

See what changed across the whole market.

Key fundamentalsEditorial reference

The anchor data BazaarBaazi references when reading the DRREDDY chart. Not a substitute for a registered research note.

Reference chart7 Oct 2025

The daily frame the desk reads on DRREDDY.

FAQ13 reader questions · AEO-eligible

The line on DRREDDY, distilled and schema-marked for AI Overview, Perplexity, and reader search.

Related stock views

The names BazaarBaazi reads alongside DRREDDY, each a living view refreshed every end-of-day run.